

## **Revised agreement for the commercialization of TRAMCET<sup>®</sup> Combination Tablets for the relief of chronic non-cancer pain and pain after tooth extraction**

---

This material is an English translation of the press release issued on September 30, 2016 in Japanese, and the Japanese release is given priority regarding content and interpretation.

September 30, 2016

Mochida Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Japan, President: Naoyuki Mochida, hereinafter called "Mochida") and Janssen Pharmaceutical K.K. (Headquarters: Tokyo, Japan, President: Chris Hourigan, hereinafter called "Janssen") have signed a revised agreement for the commercialization of TRAMCET<sup>®</sup> Combination Tablets (generic name: tramadol hydrochloride/acetaminophen) for the relief of chronic non-cancer pain and pain after tooth extraction for which Janssen holds the marketing authorization.

### 1. Reason of the change of the commercialization framework

By the change of the commercialization framework, both companies aim at the efficiency of the commercialization of TRAMCET<sup>®</sup> Combination Tablets.

### 2. Contents of the agreement

Under the new strategy, effective January 2, 2017, a co-promotion agreement replaces the original co-marketing agreement signed for TRAMCET<sup>®</sup> Combination Tablets in August 2013.

Distribution of the product currently conducted by both Mochida and Janssen will be solely led by Mochida. Janssen will continue to hold the marketing authorization for TRAMCET<sup>®</sup> Combination Tablets in Japan and supply the product to Mochida. Both companies will continue to collaborate closely on promotional activities.

Under the new commercialization framework, both companies will make a further commitment to helping patients and medical professionals relieve their burden of chronic pain and pain after tooth extraction in Japan.

### 3. Counterparty

Janssen Pharmaceutical K.K.

### 4. Schedule

- (1) Date of board resolution September 30, 2016
- (2) Date of contract September 30, 2016
- (3) Date of commencement of the revised agreement January 2, 2017

### 5. Future prospects

This agreement will have only a minor impact on the consolidated performance of Mochida for the fiscal year ending March 2017. It is expected that its impact on the consolidated sales will be an increase of approximately 15 billion JPY and that on the consolidated profit will be minor for the fiscal year ending March 2018 and the fiscal year ending March 2019.